Ipsen’s Onivyde Failed to Meet Primary Endpoint in SCLC Phase 3 Study

Ipsen’s Onivyde (irinotecan liposomal injection) failed to meet the primary endpoint of overall survival in phase 3 study investigating the drug in participants with small cell lung cancer (SCLC) who had progressed on or after platinum-based first-line therapy treatment.

The study compared Onivyde with topotecan, a chemotherapy drug. Although it did not achieve the primary endpoint, participants given Onivyde did show double the objective response rate.

“These data confirm the complexities associated with treating small cell lung cancer,” said Howard Mayer, Ipsen’s head of research and development.

The company said it will continue to explore the potential Onivyde in several areas, including as a first-line treatment for pancreatic ductal adenocarcinoma.